Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relatlimab alone and with nivolumab in advanced solid tumors
jRCT2080223834Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of relatlimab and nivolumab in Nonhematologic neoplasms, melanoma, non-small cell lung cancer (NSCLC) and 8 more (2 arms), sponsored by Bristol Myers Squibb. Started Mar 2018; status: completed.
02
Drugs
relatlimabnivolumab
03
Conditions
Nonhematologic neoplasmsmelanomanon-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)gastric cancer (GC)
Beyond the preview
Go deeper on jRCT2080223834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223834.